Cibus Welcomes the European Union’s Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward
Cibus (Nasdaq: CBUS) welcomes major progress in EU regulation of New Genomic Techniques (NGTs) as EU member states endorse the Council's negotiating mandate on March 14th, 2025. The legislation aims to regulate plants obtained through NGTs, including gene editing, to promote sustainable agriculture and food security.
The proposal introduces an 'NGT-1' category for 'conventional-like' products that could occur naturally or through conventional breeding. These products would be exempt from GMO legislation and labeling requirements, aligning EU policy with global trading partners including North and South America, UK, India, Australia, and Japan.
The Council can now enter trilogue discussions with the EU Parliament and European Commission to finalize the legislation. Cibus's RTDS® technologies produce improved crop varieties that qualify as 'conventional-like' under the proposal, focusing on rapeseed genetics for reduced seed loss, increased disease resistance, and enhanced nutrient use efficiency.
Cibus (Nasdaq: CBUS) accoglie con favore i progressi significativi nella regolamentazione dell'UE sulle Nuove Tecniche Genomiche (NTG), poiché gli stati membri dell'UE hanno approvato il mandato di negoziazione del Consiglio il 14 marzo 2025. La legislazione mira a regolamentare le piante ottenute tramite NTG, inclusa l'editing genetico, per promuovere un'agricoltura sostenibile e la sicurezza alimentare.
La proposta introduce una categoria 'NTG-1' per i prodotti 'simili a quelli convenzionali' che potrebbero verificarsi naturalmente o attraverso l'allevamento convenzionale. Questi prodotti sarebbero esenti dalla legislazione e dai requisiti di etichettatura OGM, allineando la politica dell'UE con i partner commerciali globali, tra cui Nord e Sud America, Regno Unito, India, Australia e Giappone.
Il Consiglio può ora avviare discussioni trilogiche con il Parlamento UE e la Commissione Europea per finalizzare la legislazione. Le tecnologie RTDS® di Cibus producono varietà di colture migliorate che si qualificano come 'simili a quelle convenzionali' secondo la proposta, concentrandosi sulla genetica della colza per ridurre la perdita di semi, aumentare la resistenza alle malattie e migliorare l'efficienza nell'uso dei nutrienti.
Cibus (Nasdaq: CBUS) da la bienvenida a los avances significativos en la regulación de la UE sobre Nuevas Técnicas Genómicas (NTG), ya que los estados miembros de la UE respaldaron el mandato de negociación del Consejo el 14 de marzo de 2025. La legislación tiene como objetivo regular las plantas obtenidas a través de NTG, incluida la edición genética, para promover una agricultura sostenible y la seguridad alimentaria.
La propuesta introduce una categoría 'NTG-1' para productos 'similares a los convencionales' que podrían ocurrir de forma natural o a través de la cría convencional. Estos productos estarían exentos de la legislación y los requisitos de etiquetado de OGM, alineando la política de la UE con socios comerciales globales, incluidos América del Norte y del Sur, Reino Unido, India, Australia y Japón.
El Consejo ahora puede entrar en discusiones trilaterales con el Parlamento de la UE y la Comisión Europea para finalizar la legislación. Las tecnologías RTDS® de Cibus producen variedades de cultivos mejoradas que califican como 'similares a las convencionales' según la propuesta, enfocándose en la genética de la colza para reducir la pérdida de semillas, aumentar la resistencia a enfermedades y mejorar la eficiencia en el uso de nutrientes.
Cibus (Nasdaq: CBUS)는 2025년 3월 14일 EU 회원국들이 이사회 협상 권한을 지지함에 따라 새로운 유전자 기술(NGT)에 대한 EU 규제의 주요 발전을 환영합니다. 이 법안은 유전자 편집을 포함한 NGT를 통해 얻어진 식물을 규제하여 지속 가능한 농업과 식량 안보를 촉진하는 것을 목표로 합니다.
이 제안은 자연적으로 발생하거나 전통적인 육종을 통해 발생할 수 있는 '전통적 유사' 제품을 위한 'NGT-1' 범주를 도입합니다. 이러한 제품은 GMO 법률 및 라벨링 요구 사항에서 면제되며, EU 정책을 북미 및 남미, 영국, 인도, 호주, 일본을 포함한 글로벌 거래 파트너와 일치시킵니다.
이제 이사회는 EU 의회 및 유럽 위원회와의 삼자 회담에 들어가 법안을 최종화할 수 있습니다. Cibus의 RTDS® 기술은 제안에 따라 '전통적 유사'로 분류되는 개선된 작물 품종을 생산하며, 유채 유전학에 집중하여 씨앗 손실을 줄이고 질병 저항성을 높이며 영양소 사용 효율성을 향상시킵니다.
Cibus (Nasdaq: CBUS) se félicite des avancées significatives dans la réglementation de l'UE concernant les Nouvelles Techniques Génomiques (NTG), alors que les États membres de l'UE ont approuvé le mandat de négociation du Conseil le 14 mars 2025. La législation vise à réglementer les plantes obtenues par les NTG, y compris l'édition génétique, afin de promouvoir une agriculture durable et la sécurité alimentaire.
La proposition introduit une catégorie 'NTG-1' pour les produits 'semblables aux conventionnels' qui pourraient se produire naturellement ou par reproduction conventionnelle. Ces produits seraient exemptés de la législation sur les OGM et des exigences d'étiquetage, alignant ainsi la politique de l'UE avec celle de partenaires commerciaux mondiaux, y compris l'Amérique du Nord et du Sud, le Royaume-Uni, l'Inde, l'Australie et le Japon.
Le Conseil peut maintenant entrer dans des discussions trilatérales avec le Parlement européen et la Commission européenne pour finaliser la législation. Les technologies RTDS® de Cibus produisent des variétés de cultures améliorées qui se qualifient comme 'semblables aux conventionnels' selon la proposition, en se concentrant sur la génétique du colza pour réduire la perte de semences, augmenter la résistance aux maladies et améliorer l'efficacité de l'utilisation des nutriments.
Cibus (Nasdaq: CBUS) begrüßt die bedeutenden Fortschritte in der EU-Regulierung neuer genomischer Techniken (NGTs), da die Mitgliedstaaten der EU am 14. März 2025 das Verhandlungsmandat des Rates unterstützen. Die Gesetzgebung zielt darauf ab, Pflanzen zu regulieren, die durch NGTs, einschließlich der Genbearbeitung, gewonnen werden, um nachhaltige Landwirtschaft und Ernährungssicherheit zu fördern.
Der Vorschlag führt eine 'NGT-1'-Kategorie für 'konventionell ähnliche' Produkte ein, die natürlich oder durch konventionelle Zucht entstehen könnten. Diese Produkte wären von der GVO-Gesetzgebung und den Kennzeichnungsanforderungen ausgenommen, was die EU-Politik mit globalen Handelspartnern, einschließlich Nord- und Südamerika, dem Vereinigten Königreich, Indien, Australien und Japan, in Einklang bringt.
Der Rat kann nun in trilaterale Gespräche mit dem EU-Parlament und der Europäischen Kommission eintreten, um die Gesetzgebung abzuschließen. Die RTDS®-Technologien von Cibus produzieren verbesserte Pflanzenvarianten, die gemäß dem Vorschlag als 'konventionell ähnlich' gelten, wobei der Schwerpunkt auf der Rapsgenetik liegt, um den Saatgutverlust zu reduzieren, die Krankheitsresistenz zu erhöhen und die Nährstoffnutzungseffizienz zu verbessern.
- None.
- None.
Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security
Proposed legislation identifies a ‘conventional-like’ category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners
The agreement on the Council's negotiating mandate allows its presidency to start negotiations with the European Parliament on the final text of the regulation
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, welcomes significant progress in the regulation of New Genomic Techniques (NGTs) in the European Union (EU).
On Friday 14th March, EU member states endorsed the EU Council's (the “Council”) negotiating mandate on the regulation of plants obtained by NGTs. This important advancement enables the Council to engage in 3-way discussions (known as trilogue discussions) with the EU Parliament and the European Commission to agree the final text of the legislation prior to final adoption.
The legislation is part of a package of measures designed to ensure the sustainable use of natural resources and to strengthen the resilience of EU food systems. It describes a category of NGTs, that include products of gene editing that could be obtained in nature or by conventional breeding. These plants would be determined to be ‘conventional-like’ and once verified as NGT-1, would be exempted from the rules under the EU’s GMO legislation and would not be required to be labelled.
In addition to enabling EU growers to benefit from improved varieties, the proposed regulation would help facilitate international trade by bringing EU policy closer to that of trading partners in North and South America, the United Kingdom, India, Australia, and Japan.
“The long-awaited Council agreement is another significant milestone in the EU legislative process that aims to provide a welcome boost to innovators, particularly in academia and small and mid-sized enterprises, who are developing NGT products that can contribute to a sustainable EU agri-food system,” commented Tony Moran, Senior Vice President of International Development and Government Affairs at Cibus.
“Cibus’ RTDS® technologies produce improved crop varieties that are ‘conventional-like’ under the EU proposal. Our specific work on rapeseed customer genetics, targets reduced seed loss, increased disease resistance and enhanced nutrient use efficiency,” stated Dr. Peter Beetham, Cibus’ Interim CEO, President and COO. “We’re excited by the prospect of being able to develop these varieties under European conditions and to work with European seed companies to make our traits available to European farmers. A supportive EU regulatory framework for NGTs would have global implications as improved seed genetics using gene editing will have a clearer path to commercialization and international trade.”
About Cibus
Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding Cibus' operational performance, Cibus' strategy, future operations, prospects, and plans, including the anticipated receipt of commercial revenues and additional funding.
These forward-looking statements are based on the current expectations and assumptions of Cibus' management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. Cibus' actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: Cibus' need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; changes in expected or existing competition; challenges to Cibus' intellectual property protection and unexpected costs associated with defending intellectual property rights; increased or unanticipated time and resources required for Cibus' platform or trait product development efforts; Cibus' reliance on third parties in connection with its development activities; challenges associated with Cibus' ability to effectively license its productivity traits and sustainable ingredient products; the risk that farmers do not recognize the value in germplasm containing Cibus' traits or that farmers and processors fail to work effectively with crops containing Cibus' traits; delays or disruptions in the Company's platform or trait product development efforts, particularly with respect to its non-Rice and non-disease projects in light of the Company's realigned strategic priorities; challenges that arise in respect of Cibus' production of high-quality plants and seeds cost effectively on a large scale; Cibus' dependence on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses; regulatory developments that disfavor or impose significant burdens on gene-editing processes or products; delays and uncertainties regarding regulatory developments in the European Union; Cibus' ability to achieve commercial success; commodity prices and other market risks facing the agricultural sector; technological developments that could render Cibus' technologies obsolete; changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates; dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on Cibus' ability to execute on its business plan; and other important factors discussed in the "Risk Factors" section of Cibus' Annual Report on Form 10-K which was filed with the Securities and Exchange Commission (the "SEC") on March 21, 2024. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements.
In addition, the forward-looking statements included in this press release represent Cibus' views as of the date hereof. Cibus specifically disclaims any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus' views as of any date subsequent to the date hereof.
CIBUS CONTACTS:
INVESTOR RELATIONS
Karen Troeber
ktroeber@cibus.com
858-450-2636
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
media@cibus.com
Colin Sanford
colin@bioscribe.com
203-918-4347
FAQ
What is the significance of EU's new NGT legislation for Cibus (CBUS) operations?
How will the EU's NGT-1 category classification affect agricultural products?
What specific crop improvements is Cibus (CBUS) developing under the new EU framework?
Which countries' regulations will the new EU NGT legislation align with?
When did EU member states endorse the Council's negotiating mandate for NGT regulation?
